This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Background:
Until date, the proportion of nonclassic monocytes in type 2 diabetic mellitus patients with and without chronic periodontitis has not been evaluated based on glycemic control. The objective of this study was to compare the proportion of CD14+CD16++ monocytes in type 2 diabetic patients with and without chronic periodontitis.
Materials and Methods:
In this cross sectional study A total of sixty individuals with type 2 diabetes mellitus (n = 15/group) were recruited. Individuals were grouped based on glycosylated hemoglobin A (HbA 1c) values and the presence of chronic periodontitis; Group 1 (diabetes mellitus with good glycemic control), Group 2 (diabetes mellitus with poor glycemic control), Group 3 (diabetic mellitus with chronic periodontitis and good glycemic control), Group 4 (diabetic mellitus with chronic periodontitis and poor glycemic control). Fluorochrome-conjugated monoclonal antibodies against CD14, CD16, and human leukocyte antigen–antigen D related was used to analyze the proportion of nonclassic monocytes by flow cytometry. One-way ANOVA with Tukey's post-hoc test was used to assess the significant differences in monocyte subpopulations. The Pearson's correlation test was used to assess the relationship between hemoglobin A1c values and percentage of nonclassical monocytes. In both the above statistical tools, the value of P < 0.05 is considered as significant level.
Results:
Group 4 had the highest percentage of CD14+CD16++ monocytes 14.67% + 4.70%, followed by Group 3-9.73% + 0.60%, Group 2-9.32% + 2.03% and Group 1-5.92% + 0.63% (P < 0.001). Further, a statistically significant positive correlation between HbA (1c) levels and the proportion of CD14+CD16++ monocytes was observed.
Conclusion:
In the present study, we observed type 2 diabetes mellitus patients with poor glycemic control and chronic periodontitis showed more than two-fold increase in the proportion of nonclassic monocytes compared to type 2 diabetes mellitus patients with good glycemic control.
Diabetes mellitus, a common chronic inflammatory disease characterized by altered glucose metabolism resulting in various micro–macrovascular complication
1has a high prevalence globally with 366 million individuals suffering from it as on 2011 which is likely to increase to around 566 million by 2030.
2India is regarded to be the diabetes capital of the world.
3Indian Council of Medical Research-INdia DIABetes study conducted on 13,055 individuals in 2011 projected that 77.2 million individuals living in India were pre-diabetes state and 62.4 million individuals had diabetes mellitus.
4Glycemic control plays a pivotal role in the prevention of diabetes complications.
5,
6The prevalence of diabetes complication and its burden in the south Indian population were studied in Chennai Urban Population Study and Chennai Urban Rural Epidemiology Study and reported a high prevalence of cardiovascular complications, neuropathy, microalbuminuria, and retinopathy.
7,
8,
9,
10Mohan et al.
11conducted a study involving 20,554 Indian type 2 diabetes mellitus patients and concluded that glycemic control was very poor among Indian diabetes mellitus patients with a mean hemoglobin A1c (HbA1c) of 9.2% (77 mmol/mol). Chronic periodontitis, an inflammatory disease of microbial etiology affects the supporting structures of the teeth causing resorption of alveolar bone and eventually leading to tooth mobility and tooth loss.
12The two-way relationship between diabetes mellitus and chronic periodontitis has been studied extensively over decades.
13Diabetes mellitus is also considered to be a risk factor for chronic periodontitis.
12Chronic periodontitis is considered to be the 6
thcomplication of diabetes mellitus.
14Maintaining a healthy periodontium is essential for achieving good long-term control of diabetes mellitus.
15Inflammation has been suggested to be a link between diabetes mellitus and chronic periodontitis and immune response seems to modulate the pathogenesis of the diseases. Monocytes are one of the potent immune cells which are known to exist in three subsets in humans.
16The monocytes are categorized into classical, intermediate, and nonclassical monocyte subsets based on the expression of CD14 and CD16 receptors. Classical monocytes account for 90% of circulatory blood monocytes and express only CD14 and do not express CD16 (CD14++ CD16-), the nonclassical monocytes express both CD14 and CD16 (CD14+CD16++) and account for about 10% of the monocytes.
16The nonclassical subsets of monocytes are known to be elevated in infection and inflammation.
17The nonclassical monocytes are also referred to as pro-inflammatory monocytes owing to its increased production of pro-inflammatory cytokines in response to bacterial challenge.
18Yang et al.
19suggested that the disturbance of pro-inflammatory monocytes occurs in type 2 diabetes mellitus patients. Nagasawa et al.
20revealed an increase in pro-inflammatory (CD16+) monocytes in chronic periodontitis patients compared to healthy controls and concluded that monitoring the surface expression of CD14 and CD16 receptors in chronic periodontitis patients could help in studying the alteration of monocytes in these patients. Furthermore, we have recently shown that in chronic periodontitis patients the nonclassical subset of the CD16-positive monocytes is increased compared to healthy controls.
21Until date, the proportion of nonclassical (CD14+CD16++) monocytes in type 2 diabetes mellitus with and without chronic periodontitis have not been evaluated based on glycemic control. The primary objective of the present study was to compare the proportion of CD14+CD16++ monocytes in peripheral blood of type 2 diabetes mellitus patients with and without chronic periodontitis. The secondary objective was to determine whether a correlation exists between the HbA1c levels in type 2 diabetes mellitus patients and the proportion of CD14+CD16++monocyte subset.
Materials and Methods
In this cross sectional study a total of 60 individuals with type 2 diabetes mellitus in the age range of 45–55 years were recruited from January 2014 to May 2014. The study was approved by the Institutional Ethics Committee (REF: IECNI/10/MAY/16/14). The study was conducted in accordance with the Helsinki Declaration of 1975, as revised in 2000. Individuals were recruited after obtaining a written informed consent.
Sample size
Studies evaluating the monocyte subpopulation in diabetes patients with or without chronic periodontitis have not been performed earlier. Hence, the sample size for the present study was calculated based on the studies by Nagasawa et al.
20and Bae et al.
22The mean percentage of nonclassical monocytes in type 2 diabetes mellitus patients without cardiovascular diseases
22was found to be 10.1% ± 1.4% and in chronic periodontitis patients
20it was found to be 13% ± 1.3%. Based on this mean ± standard deviation (SD); to achieve a power of 90% and α = 5%, the sample size of 15 per group was obtained.
Patient selection
Patients were diagnosed to have type 2 diabetes mellitus based on the guidelines of American Diabetic Association standards of medical care in diabetes.
23In brief, the diagnosis of diabetes was made if HbA1c ≥6.5% (48 mmol/mol) or fasting plasma glucose of ≥126 mg/dl; fasting is defined as no caloric intake for at least 8 h or 2 h plasma glucose of ≥200 mg/dl or a patient with classical symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose of ≥200 mg/dl. The case definition for chronic periodontitis was based on the guidelines given by International Workshop for a Classification of Periodontal Diseases and Conditions 1999
24(i.e.,) presence of at least 10 natural teeth; ≥30% of periodontal sites examined with ≥1 mm of attachment loss. HbA1c value of <7% (<53 mmol/mol) was considered good glycemic control and HbA1c value of >7% (>53 mmol/mol) was considered poor glycemic control.
25A total of 60 patients were recruited into four groups (n = 15) based on the HbA1c values and the presence of chronic periodontitis. Patients were sampled separately for each group to obtain the desired sample size of 15 per group. Group 1 included type 2 diabetes mellitus patients with good glycemic control without chronic periodontitis, Group 2 included type 2 diabetes mellitus patients with poor glycemic control without chronic periodontitis, Group 3 included type 2 diabetes mellitus patients with good glycemic control and chronic periodontitis and Group 4 included type 2 diabetes mellitus with poor glycemic control and chronic periodontitis. Exclusion criteria for all the groups were as follows: pregnant and lactating mothers, smokers both former and present, any periodontal or antibiotic therapy in the past 6 months, any systemic disease or condition other than diabetes mellitus, and patients with diabetes-related complication. All the study participants underwent medical examination to rule out diabetes-related complications. The absence of retinopathy was confirmed by fundus examination to rule out microaneurysms. The study participants were considered to have the macrovascular disease if they had reported a history of abnormal investigation or prior macrovascular event. All patients underwent a complete full mouth periodontal examination on all teeth excluding 3
rdmolars using a manual periodontal probe (UNC15, Hu-Friedy, Chicago, IL). Pocket probing depth (distance between gingival margin to base of gingival sulcus, in millimeters), clinical attachment loss, (distance between cement-enamel junction and base of gingival sulcus in millimeters), were recorded.
Peripheral blood collection
Three milliliters of peripheral blood samples were taken collected in two separate vacutainers from each patient. One sample was analyzed for plasma glucose levels and HbA1c level. HbA1c was measured by high-performance liquid chromatography. The blood from the second vacutainer was subjected to flow cytometric analysis.
Flow cytometric analysis
Monocyte subpopulation was analyzed based on the specific fluorochrome-conjugated monoclonal anti-human antibodies (BD Biosciences, San Jose, CA) CD14 phycoerythrin (PE) and CD16 fluorescein isothiocyanate (FITC). The CD14 clone is derived from hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c mice immunized with peripheral blood monocytes from a patient with rheumatoid arthritis. The CD16 clone is 3G8 FITC mouse anti-human antibody. Human leukocyte antigen–antigen D-related (HLA DR) Clone is G46-6 allophycocyanin (APC) mouse anti-human antibody. In addition, the following reagents (BD Biosciences, San Jose, CA) were used; fluorescent-activated cell sorting (FACS) lysis solution, phosphate-buffered saline (PBS) (pH 7.4), PBS with 10% fetal bovine serum (FBS), and 1% paraformaldehyde. The sample preparation and analysis of monocyte subpopulations was done as described previously.
21In brief, 200 μL of the whole-blood was taken in a FACS tube, and the fluorochrome-conjugated monoclonal antihuman antibodies of 7 μL CD14 (PE), 10 μL CD16 (FITC), and 5 μL HLA-DR (APC) were added and gently mixed. It was incubated for 30 min in the dark at room temperature (20°C–25°C); then 2 mL ×1 FACS lysing solution was added and incubated for 10 min in the dark at room temperature. The mixture was centrifuged at 500 × g for 5 min, and the supernatant was discarded. Three milliliers wash buffer (PBS with 10% FBS) was added, the centrifugation step was repeated, and the supernatant was discarded. Finally, 0.5 mL 1% paraformaldehyde solution was added and mixed thoroughly. The cells were acquired in a flow cytometer (FACS Calibur, BD Biosciences), and the results were analyzed using software (Flowjo software, Tree Star, Ashland, OR.).
Statistical analysis
The collected data were analyzed with IBM. SPSS statistics software 23.0 Version (IBM, Armonk, NY, USA). To describe about the data descriptive statistics mean and SD were used. The Shapiro Wilk's test for normality shows the data was normally distributed, hence to find the significant difference in the multivariate analysis the one-way ANOVA with Tukey's post-hoc test was used. The Pearson's correlation test was used to assess the relationship between HbA1c values and percentage of nonclassical monocytes. Data were analyzed using statistical software package (SPSS for Windows v. 23, IBM, Armonk, NY, USA). In both the above statistical tools, the P < 0.05 is considered as statistically significant level.
Results
The demographic data, clinical indices, mean HbA1c values of the study population are presented in
Table 1. The processed blood samples were acquired in the flow cytometer. Unstained sample of peripheral blood was analyzed based on forward and sideward scatter
Figure 1a and monocytes are gated as R2
Figure 1b. The numbers next to R2 represent the percentage of gated cells out of the total acquired cells. In the forward and side scatter (SSC) plot among the three subsets (lymphocytes, monocytes, neutrophils) monocytes (R2) alone were gated
Figure 1c. Further cells in R2 gate were plotted with SSC in Y-axis and HLA-DR in X-axis
Figure 1d. Only the HLA-DR+ cells were gated and monocyte subpopulations were analyzed based on CD 14 and CD16 expression.
26Three subpopulations of monocytes could be identified; CD14++CD16-(classical monocytes), CD14++CD16+ (intermediate monocytes), CD14+CD16++ [nonclassical monocytes;
Figure 1e.
Figure 2shows monocyte subpopulations of one sample from each group.{Table 1}
Flow cytometric analysis and gating of monocytes in peripheral blood. (a) Unstained sample of peripheral blood analyzed based on forward and sideward scatter and monocytes are gated as R2. The numbers next to R2 represent the percentage of gated cells out of the total acquired cells. (b) Unstained sample of peripheral blood; the cells in gate R2 were analyzed. (c) Peripheral blood sample was stained with phycoerythrin-conjugated anti-CD14; fluorescein isothiocyanate-conjugated anti-CD16 and allophycocyanin-conjugated anti-human leukocyte antigen–antigen D-related. Based on forward and sideward scatter among the three subsets (lymphocytes, monocytes, neutrophils) monocytes alone were gated as R2. (d) The cells in gate R2 were analyzed based on side scatter and human leukocyte antigen–antigen D-related expression. (e) Human leukocyte antigen–antigen D-related + cells were gated and monocyte subpopulations were analysed based on the expression of phycoerythrin-conjugated anti-CD14, fluorescein isothiocyanate-conjugated anti-CD16. Upper left gate (CD14++CD16-classical monocytes), Upper right gate (CD14++CD16+ Intermediate monocytes), Lower right gate (CD14+CD16++ Non classical monocytes).
Figure 1
Representative sample from four groups (a) Group 1 (diabetes mellitus with good glycemic control). (b) Group 2 (diabetes mellitus with poor glycemic control). (c) Group 3 (diabetes mellitus with chronic periodontitis and good glycemic control). (d) Group 4 (diabetes mellitus with chronic periodontitis and poor glycemic control).
Figure 2
Monocyte subpopulations in peripheral blood
The percentage of subset of monocyte in each group is presented in
Table 2. Group 4 had the highest percentage of CD14+CD16++ monocytes 14.54% ± 3.7%, followed by Group 3-9.93% ± 1.6%, Group 2-9.42% ± 1.93% and Group 1-5.82% ± 1.3% (P < 0.001, one-way ANOVA). Post hoc analysis using Tukey HSD test revealed statistically significant difference in the mean proportion of classical and intermediate monocytes among all the four groups P < 0.001. Were as in the nonclassical monocytes Group 2 vs. Group 3 alone did not show statistical significance.{Table 2}
All three monocyte subpopulations differed significantly in HLA-DR expression in all the four groups as measured by the median fluorescent intensity (MFI). Intermediate monocytes had the highest MFI for HLA-DR (861.7 ± 24.4 – Group 1, 883.1 ± 26.2 – Group 2, 885.8 ± 60.7 – Group 3, 882.1 ± 54.2 – Group 4), followed by nonclassical monocytes (270.3 ± 41.4 – Group 1, 272.5 ± 38.7 – Group 2, 261.1 ± 56.4 – Group 3, 312.3 ± 36.7 – Group 4) and classical monocytes (96.3 ± 9.2 – Group 1, 96.5 ± 6.8 – Group 2, 95.1 ± 8.0 – Group 3, 93.6 ± 13.3 – Group 4), respectively. This finding is in accordance with previously published studies.
27,
28
Glycosylated hemoglobin and CD14+CD16++ monocytes
The correlation between HbA1c values and CD14+CD16++ monocytes was analyzed using Pearson's correlation. HbA1c value showed a significant positive correlation with the percentage of CD14+CD16++ monocytes in Group 1, Group 2, and Group 4
Figure 3.
Pearson's Correlation test to assess the relationship between hemoglobin A1c values and percentage of non classical monocytes. (a) Diabetes Mellitus Type 2 good glycemic control, (b) Diabetes Mellitus Type 2 poor glycemic control, (c) diabetes Mellitus Type 2 good glycemic control with chronic periodontitis, (d) Diabetes Mellitus Type 2 poor glycemic control with chronic periodontitis. *Statistically significant
P< 0.001.
Figure 3
Discussion
Several evidence-based studies have shown increased periodontal destruction in diabetes mellitus patients.
29,
30,
31,
32,
33,
34,
35Diabetes mellitus is regarded as one of the risk factors for chronic periodontitis.
36,
37Diabetes patients in general have higher prevalence of periodontitis, more severe periodontal destruction compared to non-diabetes controls.
38,
39Taylor
40suggested a bi-directional relationship between diabetes mellitus and chronic periodontitis. The author hypothesized that diabetes mellitus could increase the susceptibility to develop chronic periodontitis and chronic periodontitis could contribute to increase hyperglycemia in diabetes patients and cause elevation of HbA1c in nondiabetes individuals.
40Chen et al.
39reported full mouth mean probing depth to be a predictor variable for increased HbA1c; after adjusting for age, gender, and Body Mass Index. Bandyopadhyay et al.
41stated that individuals with poor glycemic control had significantly higher odds of progression of pocket probing depth compared to those with good glycemic control. Nesse et al.
38assessed a dose-response relationship between periodontal inflamed surface area and HbA1c levels in type 2 diabetes mellitus and concluded that periodontal inflammation could contribute to poor glycemic control which in turn could increase the severity of periodontitis.
38Inflammation has shown to be a negative influence on glycemic control.
42Pro-inflammatory mediators such as tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-1 on entering systemic circulation could induce insulin resistance.
43The human periodontium acts as a reservoir of cytokines and poses an inflammatory burden; whereby pro-inflammatory cytokines could enter systemic circulation and cause insulin resistance.
44Increased periodontal destruction seen in type 2 diabetes mellitus patients has been attributed to the hyperinflammatory monocyte trait in these individuals.
45CD14+CD16++ subpopulation of circulating monocytes has been shown to be elevated in type 2 diabetes mellitus patients as compared to normal controls.
22Similarly, this subpopulation of monocytes was expanded in chronic periodontitis patients compared to healthy controls
20,
21In the present study, we observed that type 2 diabetes mellitus patients with poor glycemic control and chronic periodontitis showed more than two-fold increase in the proportion of nonclassical monocytes compared to type 2 diabetes mellitus patients with good glycemic control. Further a positive correlation between HbA1c levels and the proportion of CD14+CD16++ monocytes was observed. Yang et al.
19stated that disturbance of nonclassical monocytes observed in type 2 diabetes mellitus patients could be related to the activation of TLR-4/NFκB signaling pathways underlying the immune abnormalities of CD14+CD16++ monocytes. Diabetes-related complication status has been reported to have an impact on the circulating monocyte phenotype.
46Min et al.
46analyzed the alterations of monocyte CD16 in diabetes patients with and without complications. The authors reported that compared to controls, the percentage of circulating nonclassical monocytes were higher in diabetes patients without complications. The authors concluded by stating that diabetes did not affect the white blood cells but increased the monocytes. Further, they reported a significant reduction in the number of non-classical monocytes in patients with diabetes-related complications. In the present study, none of the recruited patients had diabetes-related complications. CD14, CD16, HLA-DR fluorochrome antibody combination is considered to be reliable for the analysis of monocyte subsets
47and has been used in several studies.
48,
49,
50
Conclusion
One of the limitations of the present study is that the association between fasting blood glucose (FBG) and nonclassic monocytes was not assessed. FBG levels are influenced by diet, physical exercise and compliance to medication. HbA1c serves as a marker for average blood glucose level over the previous 2–3 months period. We hypothesize that the cytokine milieu or the underlying inflammatory process in periodontitis and hyperglycemic status in type 2 diabetes mellitus could trigger the classic monocytes to get converted to nonclassic monocytes, thereby contributing to increased periodontal destruction. Although this needs further investigation the results need to be interpreted with caution. Further studies/clinical trials based on the treatment of periodontitis, resolution of inflammation and alteration of nonclassical monocyte subpopulation could provide conclusive evidence on the role of these cells in the pathogenesis of chronic periodontitis and type 2 diabetes mellitus.
Acknowledgment
The authors thank Indian Council of Medical Research (ICMR) for their support as this work is a part of a PhD program supported by ICMR, New Delhi, India. The authors would also like to thank the Central Research Facility of Sri Ramachandra University, Chennai, India for providing support on flow cytometric analysis. The authors would also like to thank Professor Loems Ziegler-Heitbrock, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom for reviewing the manuscript and giving his valuable suggestions.
Financial support and sponsorship
Nil.
Conflicts of interest
The authors of this manuscript declare that they have no conflicts of interest, real or perceived, financial or nonfinancial in this article.
IsrailiZHAdvances in the treatment of type 2 diabetes mellitus20111811752WhitingDRGuariguataLWeilCShawJIDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 203020119431121JoshiSRParikhRMIndia – Diabetes capital of the world: Now heading towards hypertension2007553234AnjanaRMPradeepaRDeepaMDattaMSudhaVUnnikrishnanRPrevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: Phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study20115430227KohnerEMAldingtonSJStrattonIMManleySEHolmanRRMatthewsDRUnited Kingdom prospective diabetes study, 30: Diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors1998116297303Clustering of long-term complications in families with diabetes in the diabetes control and complicationstrialThe Diabetes Control and Complications Trial Research Group199746182939UnnikrishnanRIRemaMPradeepaRDeepaMShanthiraniCSDeepaRPrevalence and risk factors of diabetic nephropathy in an urban South Indian population: The Chennai Urban Rural Epidemiology Study (CURES 45)200730201924PradeepaRRemaMVigneshJDeepaMDeepaRMohanVPrevalence and risk factors for diabetic neuropathy in an urban South Indian population: The Chennai Urban Rural Epidemiology Study (CURES-55)20082540712MohanVDeepaRRaniSSPremalatha G; Chennai Urban Population Study (CUPSNo5).Prevalence of coronary artery disease and its relationship to lipids in a selected population in South India: The Chennai Urban Population Study (CUPS no 5)2001386827PremalathaGShanthiraniSDeepaRMarkovitzJMohanVPrevalence and risk factors of peripheral vascular disease in a selected South Indian population: The Chennai Urban Population Study2000231295300MohanVShahSSabooBCurrent glycemic status and diabetes related complications among type 2 diabetes patients in India: Data from the A1chieve study201361125OffenbacherSPeriodontal diseases: Pathogenesis1996182178GrossiSGGencoRJPeriodontal disease and diabetes mellitus: A two-way relationship199835161LöeHPeriodontal disease.The sixth complication of diabetes mellitus19931632934TaylorGWBurtBABeckerMPGencoRJShlossmanMKnowlerWCSevere periodontitis and risk for poor glycemic control in patients with non-insulin-dependent diabetes mellitus199667108593Ziegler-HeitbrockLAncutaPCroweSDalodMGrauVHartDNNomenclature of monocytes and dendritic cells in blood2010116e7480Ziegler-HeitbrockLThe CD14+CD16+ blood monocytes: Their role in infection and inflammation20078158492BelgeKUDayyaniFHoreltASiedlarMFrankenbergerMFrankenbergerBThe proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF2002168353642YangMGanHShenQTangWDuXChenDProinflammatory CD14+CD16+ monocytes are associated with microinflammation in patients with type 2 diabetes mellitus and diabetic nephropathy uremia20123538896NagasawaTKobayashiHAramakiMKijiMOdaSIzumiYExpression of CD14, CD16 and CD45RA on monocytes from periodontitis patients200439728JagannathanRLavuVRaoSRComparison of the proportion of non-classic (CD14+CD16+) monocytes/macrophages in peripheral blood and gingiva of healthy individuals and patients with chronic periodontitis2014858528BaeSYYoonSYKimYKCD14/CD16 subpopulations of circulating monocytes in type 2 diabetes mellitus patients with/without coronary artery disease2001215206American DiabetesAssociationStandards of medical care in diabetes–2014201437 Suppl 1S1480ArmitageGCDevelopment of a classification system for periodontal diseases and conditions1999416MendesABFittipaldiJANevesRCChacraARMoreira EDJrPrevalence and correlates of inadequate glycaemic control: Results from a nationwide survey in 6,671 adults with diabetes in Brazil20104713745HijdraDVorselaarsADGruttersJCClaessenAMRijkersGTDifferential expression of TNFR1 (CD120a) and TNFR2 (CD120b) on subpopulations of human monocytes2012938RossolMKrausSPiererMBaerwaldCWagnerUThe CD14(bright) CD16+monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population2012646717WongKLTaiJJWongWCHanHSemXYeapWHGene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets2011118e1631NovakMJPotterRMBlodgettJEbersoleJLPeriodontal disease in Hispanic Americans with type 2 diabetes20087962936AwartaniFAEvaluation of the relationship between type 2 diabetes and periodontal disease2009309026TsaiCHayesCTaylorGWGlycemic control of type 2 diabetes and severe periodontal disease in the US adult population20023018292MatthewsDCThe relationship between diabetes and periodontal disease2002681614CutlerCWMachenRLJorwaniRIacopinoAMHeightened gingival inflammation and attachment loss in type 2 diabetics with hyperlipidemia199970131321GarciaRPeriodontal treatment could improve glycaemic control in diabetic patients200910201KaurGHoltfreterBRathmannWSchwahnCWallaschofskiHSchipfSAssociation between type 1 and type 2 diabetes with periodontal disease and tooth loss20093676574DeshpandeKJainASharmaRPrasharSJainRDiabetes and periodontitis20101420712Van DykeTESheileshDRisk factors for periodontitis2005737NesseWLindeAAbbasFSpijkervetFKDijkstraPUde BrabanderECDose-response relationship between periodontal inflamed surface area and HbA1c in type 2 diabetics200936295300ChenLWeiBLiJLiuFXuanDXieBAssociation of periodontal parameters with metabolic level and systemic inflammatory markers in patients with type 2 diabetes20108136471TaylorGWBidirectional interrelationships between diabetes and periodontal diseases: An epidemiologic perspective2001699112BandyopadhyayDMarlowNMFernandesJKLeiteRSPeriodontal disease progression and glycaemic control among Gullah African Americans with type-2 diabetes2010375019SchmidtMIDuncanBBSharrettARLindbergGSavagePJOffenbacherSMarkers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis risk in communities study): A cohort study1999353164952FeingoldKRGrunfeldCRole of cytokines in inducing hyperlipidemia199241 Suppl 297101EngebretsonSChertogRNicholsAHey-HadaviJCelentiRGrbicJPlasma levels of tumour necrosis factor-alpha in patients with chronic periodontitis and type 2 diabetes2007341824BeckJGarciaRHeissGVokonasPSOffenbacherSPeriodontal disease and cardiovascular disease199667112337MinDBrooksBWongJSalomonRBaoWHarrisbergBAlterations in monocyte CD16 in association with diabetes complications20122012649083AbelesRDMcPhailMJSowterDAntoniadesCGVergisNVijayGKCD14, CD16 and HLA-DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA-DR expression by CD14(hi)/CD16(neg) monocytes: Expansion of CD14(hi)/CD16(pos) and contraction of CD14(lo)/CD16(pos) monocytes in acute liver failure20128182334ZawadaAMRogacevKSSchirmerSHSesterMBöhmMFliserDMonocyte heterogeneity in human cardiovascular disease2012217127384TalloneTTurconiGSoldatiGPedrazziniGMoccettiTVassalliGHeterogeneity of human monocytes: An optimized four-color flow cytometry protocol for analysis of monocyte subsets201142119AmirOSpivakILaviIRahatMAChanges in the monocytic subsets CD14(dim)CD16(+) and CD14(++)CD16(-) in chronic systolic heart failure patients20122012616384